UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 1-6571 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 22-1918501 (State or other jurisdiction o ...

Merck & Co., Inc. (NYSE:MRK) Q1 2024 Results Conference Call April 25, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Dana Graybosch - Leerink Partners James Shin - Deutsche Bank Umer Raffat - Evercore Tim Anderson - Wolfe Research Louise Chen - Cantor Fitzgerald Trun ...

Merck (MRK) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% excluding foreign exchange (Fx) impact.Including acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items, earnings were $1.87 per share, up 76% ex Fx.Revenues rose 9% year over year (12% excluding Fx) to $15.78 billion. Sales beat the ...

Key TakeawaysMerck beat earnings and revenue estimates on strong sales of its Keytruda cancer medicine and Gardasil HPV vaccine.The pharmaceutical giant explained that results would have been even better except for the impact of the devaluation of the Argentine peso.Merck raised and narrowed its outlook for 2024 profit and sales. Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on str ...

For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over the same period last year. EPS came in at $2.07, compared to $1.40 in the year-ago quarter.The reported revenue represents a surprise of +2.95% over the Zacks Consensus Estimate of $15.32 billion. With the consensus EPS estimate being $1.94, the EPS surprise was +6.70%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next m ...

Exhibit 99.1 News Release Merck Announces First-Quarter 2024 Financial Results - Sales Reflect Continued Strong Growth in Oncology and Vaccines - Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 12% o KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24% o GARDASIL/GARDASIL 9 Sales Grew 14% to $2.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 17% - GAAP EPS Wa ...

Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey.Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 bill ...

BRAZIL - 2024/02/04: In this photo illustration, the Merck Sharp and Dohme logo is displayed on a ... [+] smartphone screen and in the background. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates. As usual, Keytruda will be the driving growth ...

Merck (MRK) will report first-quarter 2024 results on Apr 25, before market open. In the last reported quarter, the company delivered an earnings surprise of 133.3%.Factors to ConsiderThe Zacks Consensus Estimate for Merck’s total revenues is $15.34 billion. The Zacks Consensus Estimate for Merck’s Pharmaceutical unit is $13.53 billion, while our estimate is $13.50 billion.In the Pharmaceuticals segment, strong global underlying demand across its business, particularly for cancer drug Keytruda and HPV vacci ...

Wall Street analysts forecast that Merck (MRK) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their i ...